Skip to content Skip to footer

Melanotan 1 vs Melanotan 2: Structure, Receptor Selectivity and Regulatory Status Compared

Short answer: Melanotan 1 (MT-1) and Melanotan 2 (MT-2) are two different synthetic analogues of α-melanocyte-stimulating hormone (α-MSH). MT-1 is a linear peptide of 13 amino acids with two modifications. MT-2 is a much shorter, cyclic heptapeptide. They share a family but not a structure, and they differ in how selectively they bind the five melanocortin receptors. Only MT-1, under the name afamelanotide, has been developed into an authorised medicine, for a rare condition. This guide compares them as laboratory molecules. It does not discuss use in people and nothing here is tanning or use advice.

Where both molecules come from: α-MSH

α-MSH is a 13-amino-acid peptide hormone cut from a larger precursor, pro-opiomelanocortin (POMC). It acts on a family of five G-protein-coupled receptors, MC1R to MC5R. Those receptors are involved in pigmentation (MC1R), energy balance and appetite (MC3R, MC4R), exocrine function (MC5R) and other pathways. Native α-MSH is rapidly broken down in tissue, which makes it a poor research tool for anything that needs a stable signal.

Both melanotans were designed to fix that. Chemists at the University of Arizona, in work published around 1980, changed the sequence to make it more potent and more stable. That is the shared origin. After that, the two molecules go separate ways.

Melanotan 1: the linear analogue

MT-1 is a linear 13-residue peptide that keeps the α-MSH sequence but swaps two residues: norleucine replaces methionine at position 4, and D-phenylalanine replaces L-phenylalanine at position 7. The original description is in Sawyer et al., Proceedings of the National Academy of Sciences, 1980, titled “4-Norleucine, 7-D-phenylalanine-α-melanocyte-stimulating hormone: a highly potent α-melanotropin”. In the literature it appears under several names: NDP-α-MSH, [Nle⁴, D-Phe⁷]-α-MSH, and afamelanotide.

The two substitutions have clear chemical logic. Norleucine is an isosteric replacement for methionine that removes an oxidation-prone sulfur. D-phenylalanine resists enzymes that cleave at the L-form and also changes the shape of the key binding region. Together they give a peptide that is more potent and longer-lived in tissue than native α-MSH. MT-1 is still a fairly large linear molecule, and it retains α-MSH’s pattern of activity across the melanocortin receptors, with high potency at MC1R.

For our own catalogue entry, see Melanotan 1 for laboratory research.

Melanotan 2: the cyclic heptapeptide

MT-2 is a different design. Instead of keeping the whole chain, it keeps only the core “message sequence” His-Phe-Arg-Trp and constrains it into a ring. It is a cyclic lactam: a bond between the side chains of an aspartate and a lysine closes the ring, and D-phenylalanine and norleucine are again used to boost potency and stability. The structural logic was developed through NMR and molecular-dynamics work on linear and cyclic melanotropins; Al-Obeidi and colleagues (Journal of Peptide Research, 1998) describe NMR and quenched molecular dynamics studies of superpotent linear and cyclic α-melanotropins, which gives a good picture of why cyclisation was used.

The result is a smaller, more rigid molecule. Because the ring fixes the conformation, MT-2 binds strongly to several receptors, not just MC1R. That broader receptor profile is the main pharmacological difference between the two compounds, and it is why MT-2 has been used in preclinical work on pathways beyond pigmentation. Our complete MT-2 research guide covers that literature, and the structural relationship to a related compound is set out in Melanotan 2 versus PT-141.

A side-by-side comparison

  • Length and shape: MT-1 is linear with 13 residues; MT-2 is a cyclic heptapeptide, much smaller and more constrained.
  • Origin: both are analogues of α-MSH; MT-1 changes two residues, MT-2 keeps the core sequence and cyclises it.
  • Receptor profile: MT-1 is potent at MC1R and retains some activity at other melanocortin receptors; MT-2 is notably less selective and acts strongly across several receptor subtypes.
  • Stability: both resist degradation better than α-MSH, through D-amino acid and norleucine substitution; MT-2 gains further stability from its ring.
  • Medicinal development: MT-1 as afamelanotide has been developed into an authorised product; MT-2 has not been authorised as a medicine anywhere that we are aware of.

Researchers choosing between the two for a receptor-pharmacology experiment should look at the receptor binding and functional assay data for the exact receptor of interest, not at the shared “melanotan” label. A profile that fits MC1R work does not necessarily suit an MC4R study.

Afamelanotide: what the regulatory story actually is

The only reason MT-1 has a substantial clinical literature is a rare disease. Afamelanotide was studied in erythropoietic protoporphyria (EPP), a condition in which light exposure causes severe pain. Langendonk and colleagues (New England Journal of Medicine, 2015) reported two phase 3 trials of afamelanotide in EPP, and the product was subsequently authorised for that condition in the EU and later by the US FDA. Those are decisions about a licensed formulation, for a defined patient group, under medical supervision.

That context matters because it is regularly misunderstood. An authorised medicine for a rare disease is not evidence about an unlicensed research vial, and the regulatory history of afamelanotide says nothing about MT-2. UK readers should also know that the Medicines and Healthcare products Regulatory Agency has warned the public about unlicensed melanotan products; see the MHRA for current guidance. Our products are supplied for laboratory research only, and this site does not recommend or describe use in people.

Practical points for laboratory work

  • Name carefully. “Melanotan” alone is ambiguous. Specify MT-1 (afamelanotide, NDP-α-MSH) or MT-2 in protocols and records, and state the sequence.
  • Confirm identity. Linear and cyclic peptides differ in mass and in HPLC behaviour. A batch-matched certificate with mass-spectrometry confirmation lets you check which molecule is in the vial. Batches from Peptides Lab UK are HPLC & COA Verified.
  • Plan dilutions on paper. Use the peptide calculator for mass-to-concentration conversions; this is arithmetic for laboratory work only.
  • Handle for stability. Store lyophilised material as the certificate states, and keep a record of freeze-thaw history.

If MT-2 is the molecule you need, the MT-2 product page lists the format.

What the comparison does not tell you

It is easy to over-read a comparison table. The facts above describe chemistry and receptor pharmacology in published papers. They do not describe the outcome of using either molecule in a person, and this guide takes no position on that. Published preclinical findings should be read in their own context, with attention to species, route and design, and independent replication should be sought before treating any single result as settled.

How the melanocortin receptor family is organised

The melanocortin system is small enough to describe in a paragraph. There are five receptors, all G-protein-coupled. MC1R is found mainly on melanocytes and is the receptor most associated with pigmentation. MC2R is the ACTH receptor of the adrenal cortex and is not activated by α-MSH or by the melanotans. MC3R and MC4R are expressed in the brain and are linked to energy homeostasis in animal studies. MC5R is found in exocrine glands and other tissues. When a paper says an analogue is “non-selective”, it usually means that the compound activates MC1R, MC3R, MC4R and MC5R with comparable potency, while “selective” would mean a clear separation between receptors. That vocabulary is the right lens for comparing MT-1 and MT-2.

Potency is not selectivity

A second trap in the literature is to confuse a low EC50 or Ki, which means a compound acts at low concentration, with selectivity, which means it prefers one receptor over another. A “superpotent” analogue can be potent at every receptor in the family. MT-1 and MT-2 were both described as superpotent when first characterised, but potency was the design goal. Selectivity, the property most laboratories need today, came later and mostly through different compounds. Anyone planning receptor-specific work should look for assay data that report activity across all relevant subtypes in the same cell system, so that numbers can be compared fairly.

Frequently asked questions

For the supplier-evidence side of this topic, see our best research peptides UK checklist and our guide to where to buy peptides in the UK.

What is Melanotan 1 vs 2?

Both are synthetic α-MSH analogues. Melanotan 1 (afamelanotide, NDP-α-MSH) is a linear 13-residue peptide with norleucine at position 4 and D-phenylalanine at position 7. Melanotan 2 is a smaller cyclic heptapeptide built around the His-Phe-Arg-Trp core. They differ in structure and in melanocortin receptor selectivity.

Is Melanotan 1 the same as afamelanotide?

Yes, in the research literature MT-1, NDP-α-MSH, [Nle4, D-Phe7]-α-MSH and afamelanotide refer to the same linear peptide. Afamelanotide is the name used for the authorised medicinal product.

Which melanotan is more selective?

MT-1 is potent at MC1R but also retains activity at other melanocortin receptors; MT-2 is generally described as less selective and binds several subtypes strongly. Check binding and functional data for the specific receptor in your assay.

Is Melanotan 2 an authorised medicine?

Not to our knowledge. Afamelanotide (MT-1) has been authorised for a rare condition; MT-2 has not been authorised as a medicine. The MHRA has warned about unlicensed melanotan products in the UK.

How should I tell which melanotan is in a vial?

Use the certificate of analysis: the stated sequence or molecular weight and the mass-spectrometry result should match the molecule you ordered, and the batch number should match the vial.

Peptides Lab UK products are supplied for laboratory research use only, not for human or veterinary use. This article is educational and is not medical advice.

Leave a comment

0.0/5

99% Purity Guarantee
Trusted By Researchers
★★★★★
Celebrating 500,000 Orders
Third party verified